CTI Life Sciences Fund

We’re excited to welcome Charlotte Sénéchal to CTI Life Sciences Fund as our newest Analyst, based in Montreal! Charlotte joins CTI after completing our internship program and brings a strong scientific background in human genetics and cell biology, with a PhD in Human Genetics from McGill University. Her research focused on G-protein coupled receptor biology and muscle stem cell regeneration, with implications for aging and muscular dystrophies. She also brings experience across academic and healthcare research and a passion for translating innovative science into meaningful therapeutic opportunities. In her new role, Charlotte will be working closely with the CTI team on deal sourcing, scientific and clinical due diligence, and the evaluation of emerging life sciences companies. If you’re building an innovative life sciences company or working on an exciting opportunity, we encourage you to connect with Charlotte and introduce yourself. Welcome to the team, Charlotte! We’re excited to have you on board.

Congratulations to Dr. Perreault Claude on being named a Chevalier de l’Ordre national du Québec, the highest distinction awarded by the Government of Québec. This prestigious honour recognizes a lifetime of extraordinary contributions to science, medicine, and innovation, as well as his profound impact on improving the lives of patients through groundbreaking research. As co-founder of Epitopea, Claude has helped pioneer a new frontier in cancer immunotherapy through the discovery of a novel class of tumor-specific antigens, opening the door to potentially transformative cancer vaccines and immunotherapies. At CTI Life Sciences Fund, we are incredibly proud to support Claude and the Epitopea team alongside our valued partners, Fonds de solidarité FTQ, Investissement Québec, and adMare BioInnovations It is a privilege to back visionary scientists and entrepreneurs whose work has the potential to redefine the future of cancer treatment. Congratulations, Claude, on this well-deserved recognition. Your scientific leadership, dedication to patients, and commitment to innovation continue to inspire the entire life sciences community. https://lnkd.in/ga5TwDxT

We are looking for an in-person intern to start at our Montreal offices for an unforgettable Summer Internship in Life Sciences VC! If you always wondered about the intersection of investments and Life Sciences, this internship is for you. Apply before April 30, 2026. Email all applications to ctihr@ctisciences.com #SummerInternship #CTILifeSciences #VentureCapital #LifeSciences

CTI Life Sciences Fund portfolio company, Oligon Therapeutics will present at this year’s BIOTECanada Investment Summit in Whistler. We’re excited to introduce Oligon’s self-delivering #siRNA Therapeutics platform to our investor community.

Great turnout last night at Career Night hosted by The Hospital for Sick Children (SickKids). Paul Cassar, PhD represented CTI Life Sciences Fund and the Venture Capital career path, connecting with graduate students exploring non-academic careers. The conversation highlighted how venture capital sits at the intersection of science, finance, intellectual property, and regulatory strategy — and how scientific training can translate into impact beyond the bench. The thoughtful questions and strong engagement made for energizing roundtable discussions. Proud to support the next generation of innovators as they explore diverse career paths. #VentureCapital #LifeSciences #CareerDevelopment

Exciting news at CTI Life Sciences Fund! We are thrilled to welcome two new members to the team. Their deep expertise and entrepreneurial mindset further strengthen CTI’s commitment to building and scaling impactful biotech companies. - Dana Matzen, PhD – Partner - Radhika G. – Principal We are equally proud to announce the promotion of Xin Hang from Principal to Senior Principal as a well-deserved recognition of his contributions to past investments, new company creation initiatives, and the growth of our portfolio companies Alongside our growing team, we have launched a new website with a refreshed look and feel that reflects our evolution and long-term vision. With new perspectives and a strong foundation, CTI continues to build on its legacy of creating, building, and investing in innovative biotech companies across Canada, US and Europe. https://lnkd.in/gr_eaeCN

CTI Life Sciences Fund is proud to celebrate a major milestone for our portfolio company, Kainova Therapeutics. Kainova has successfully completed the first close of its $32M Series B financing, led by Investissement Québec and supported by existing investors, including CTI Life Sciences Fund. We’re particularly excited about the continued advancement of DT-7012, Kainova’s differentiated anti-CCR8 antibody designed to selectively deplete regulatory T cells (Tregs) within the tumor microenvironment. We believe this approach holds great promise for enhancing anti-tumor immune responses and represents an innovative strategy in immuno-oncology. DT-7012 is advancing though the ongoing Phase I/II DOMISOL trial in advanced solid tumors, an important step toward translating this science into meaningful clinical impact. Congratulations to the Kainova team on this achievement. #Biotech #LifeSciences #ImmunoOncology #CancerResearch #ClinicalDevelopment #VentureCapital #PortfolioCompany Full announcement: https://lnkd.in/gnxQvtrV

CTI Life Sciences Fund is attending the 2026 OBIO Investment Summit in Toronto. Looking forward to meetings with the presenting companies.

We’re thrilled to congratulate Thryv Therapeutics Inc., a CTI Life Sciences Fund portfolio company, on the initiation of the pivotal Wave II Phase 2/3 study evaluating THRV-1268, an oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2 — a significant step forward in addressing an unmet need for patients living with this rare and potentially life-threatening genetic condition. Long QT Syndrome currently has no approved disease-modifying therapies, and launching a late-stage clinical program informed by strong early signals of QT shortening marks a noteworthy advancement in precision cardiology research and innovation. https://lnkd.in/g_6tC9Hm

Formerly Domain Therapeutics, Kainova Therapeutics enters a new chapter with a name aligned to its scientific ambition and clinical trajectory in immuno-oncology and inflammation https://lnkd.in/ghKXdx8J